Loading...

Corindus Vascular Robotics

AMEX:CVRS
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CVRS
AMEX
$596M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Corindus Vascular Robotics has significant price volatility in the past 3 months.
CVRS Share Price and Events
7 Day Returns
1.4%
AMEX:CVRS
-3.8%
US Medical Equipment
-3.9%
US Market
1 Year Returns
255.3%
AMEX:CVRS
10%
US Medical Equipment
1.4%
US Market
CVRS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corindus Vascular Robotics (CVRS) 1.4% 37.6% 131.2% 255.3% 177.9% -
US Medical Equipment -3.8% -3.9% -1.1% 10% 54.1% 90.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • CVRS outperformed the Medical Equipment industry which returned 10% over the past year.
  • CVRS outperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
CVRS
Industry
5yr Volatility vs Market

CVRS Value

 Is Corindus Vascular Robotics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Corindus Vascular Robotics. This is due to cash flow or dividend data being unavailable. The share price is $2.89.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corindus Vascular Robotics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corindus Vascular Robotics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:CVRS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.20
AMEX:CVRS Share Price ** AMEX (2019-05-15) in USD $2.89
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 38.98x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corindus Vascular Robotics.

AMEX:CVRS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:CVRS Share Price ÷ EPS (both in USD)

= 2.89 ÷ -0.20

-14.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corindus Vascular Robotics is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Corindus Vascular Robotics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Corindus Vascular Robotics's expected growth come at a high price?
Raw Data
AMEX:CVRS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
29.4%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.21x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Corindus Vascular Robotics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corindus Vascular Robotics's assets?
Raw Data
AMEX:CVRS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.01
AMEX:CVRS Share Price * AMEX (2019-05-15) in USD $2.89
United States of America Medical Equipment Industry PB Ratio Median Figure of 182 Publicly-Listed Medical Equipment Companies 4.28x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
AMEX:CVRS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:CVRS Share Price ÷ Book Value per Share (both in USD)

= 2.89 ÷ 0.01

403.46x

* Primary Listing of Corindus Vascular Robotics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corindus Vascular Robotics is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Corindus Vascular Robotics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Corindus Vascular Robotics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CVRS Future Performance

 How is Corindus Vascular Robotics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corindus Vascular Robotics expected to grow at an attractive rate?
  • Unable to compare Corindus Vascular Robotics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Corindus Vascular Robotics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Corindus Vascular Robotics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
AMEX:CVRS Future Growth Rates Data Sources
Data Point Source Value (per year)
AMEX:CVRS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 29.4%
AMEX:CVRS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 42.1%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:CVRS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:CVRS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 68 -7 1
2021-12-31 45 -22 1
2020-12-31 29 -27 -35 3
2019-12-31 18 -31 -38 3
AMEX:CVRS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 12 -38
2018-12-31 11 -32 -43
2018-09-30 10 -34 -42
2018-06-30 10 -35 -42
2018-03-31 10 -34 -40
2017-12-31 10 -32 -34
2017-09-30 6 -32 -36
2017-06-30 4 -31 -36
2017-03-31 3 -29 -35
2016-12-31 3 -28 -33
2016-09-30 3 -26 -31
2016-06-30 3 -27 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corindus Vascular Robotics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Corindus Vascular Robotics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:CVRS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Corindus Vascular Robotics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:CVRS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -0.03 -0.03 -0.03 1.00
2021-12-31 -0.09 -0.09 -0.09 1.00
2020-12-31 -0.16 -0.13 -0.18 3.00
2019-12-31 -0.18 -0.17 -0.19 3.00
AMEX:CVRS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.20
2018-12-31 -0.22
2018-09-30 -0.22
2018-06-30 -0.22
2018-03-31 -0.21
2017-12-31 -0.20
2017-09-30 -0.23
2017-06-30 -0.26
2017-03-31 -0.29
2016-12-31 -0.28
2016-09-30 -0.26
2016-06-30 -0.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corindus Vascular Robotics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corindus Vascular Robotics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corindus Vascular Robotics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CVRS Past Performance

  How has Corindus Vascular Robotics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corindus Vascular Robotics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corindus Vascular Robotics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Corindus Vascular Robotics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Corindus Vascular Robotics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Corindus Vascular Robotics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corindus Vascular Robotics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:CVRS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 12.33 -37.66 26.99 9.51
2018-12-31 10.78 -42.64 27.30 8.77
2018-09-30 10.30 -42.40 27.91 8.14
2018-06-30 9.77 -41.90 27.13 8.60
2018-03-31 10.36 -39.65 26.16 9.09
2017-12-31 9.65 -34.12 24.78 9.52
2017-09-30 6.00 -35.94 23.11 10.49
2017-06-30 4.26 -36.16 22.10 10.72
2017-03-31 2.51 -35.34 20.63 10.57
2016-12-31 2.84 -33.08 19.53 10.31
2016-09-30 3.14 -30.52 18.25 9.56
2016-06-30 2.66 -29.51 17.55 9.09
2016-03-31 3.06 -29.22 17.12 9.58
2015-12-31 2.73 -28.76 16.14 10.03
2015-09-30 2.51 -28.08 14.33 9.60
2015-06-30 2.84 -29.47 14.24 8.69
2015-03-31 3.01 -27.88 13.08 7.32
2014-12-31 2.98 -24.54 13.00 6.61
2014-09-30 2.69 -22.67 12.16 6.43
2014-06-30 2.17 -17.72 10.36 6.61
2014-03-31 1.15 -15.30 9.44 6.07
2013-12-31 0.87 -14.69 8.22 4.79
2012-12-31 0.20 -9.69 4.50 4.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Corindus Vascular Robotics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Corindus Vascular Robotics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Corindus Vascular Robotics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Corindus Vascular Robotics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corindus Vascular Robotics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CVRS Health

 How is Corindus Vascular Robotics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corindus Vascular Robotics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corindus Vascular Robotics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corindus Vascular Robotics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corindus Vascular Robotics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corindus Vascular Robotics Company Filings, last reported 1 month ago.

AMEX:CVRS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 25.11 15.39 37.76
2018-12-31 13.75 11.89 23.85
2018-09-30 19.58 11.80 29.63
2018-06-30 24.04 11.71 34.32
2018-03-31 33.25 11.62 43.95
2017-12-31 17.52 0.15 17.46
2017-09-30 24.78 0.25 26.20
2017-06-30 32.01 1.48 35.24
2017-03-31 39.59 2.64 45.23
2016-12-31 4.07 3.76 9.18
2016-09-30 13.14 4.81 18.08
2016-06-30 20.49 5.82 26.36
2016-03-31 28.18 6.79 35.32
2015-12-31 35.85 7.71 42.67
2015-09-30 42.97 8.59 50.33
2015-06-30 49.91 9.43 58.95
2015-03-31 12.71 9.27 22.02
2014-12-31 19.78 9.11 28.53
2014-09-30 25.63 4.72 29.52
2014-06-30 0.70 4.69 6.94
2014-03-31 6.29 0.00 5.72
2013-12-31 10.04 0.00 9.85
2012-12-31 24.41 0.00 25.54
  • Corindus Vascular Robotics's level of debt (61.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.8% vs 61.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Corindus Vascular Robotics has sufficient cash runway for 1.2 years based on current free cash flow.
  • Corindus Vascular Robotics has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 10.5% each year.
X
Financial health checks
We assess Corindus Vascular Robotics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corindus Vascular Robotics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CVRS Dividends

 What is Corindus Vascular Robotics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corindus Vascular Robotics dividends.
If you bought $2,000 of Corindus Vascular Robotics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corindus Vascular Robotics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corindus Vascular Robotics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:CVRS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:CVRS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corindus Vascular Robotics has not reported any payouts.
  • Unable to verify if Corindus Vascular Robotics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corindus Vascular Robotics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corindus Vascular Robotics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Corindus Vascular Robotics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corindus Vascular Robotics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corindus Vascular Robotics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CVRS Management

 What is the CEO of Corindus Vascular Robotics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Toland
COMPENSATION $2,194,146
AGE 48
TENURE AS CEO 3.2 years
CEO Bio

Mr. Mark J. Toland has been the Chief Executive Officer, President and Director of Corindus Vascular Robotics, Inc. since March 7, 2016. Mr. Toland joined Corindus from Boston Scientific Corporation, a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. He has more than 20 years of operating experience in the cardiovascular medical deviceindustry to Corindus. Mr. Toland spent more than 18 years at Boston Scientific where he led large divisional and corporate teams responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart and Electrophysiology. He is a highly respected industry veteran with proven leadership skills and an exceptional track record of growing organizations within the interventional cardiovascular industry. Since 2015, Mr. Toland has served as a Member of the Scientific Advisory Board of The International Society of Cardiovascular Translational Research, a non-profit organization founded in 2007 with a goal to expedite scientific discovery to clinical application (patients). He holds a B.S. in Business Administration from the University of Louisville.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Corindus Vascular Robotics management team in years:

3.1
Average Tenure
48
Average Age
  • The tenure for the Corindus Vascular Robotics management team is about average.
Management Team

Mark Toland

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
48
TENURE
3.2 yrs

David Long

TITLE
CFO, Senior VP
COMPENSATION
$568K
AGE
48
TENURE
4.8 yrs

Doug Teany

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
46
TENURE
3.2 yrs

Nora Dutta

TITLE
Senior Vice President of Human Resources
TENURE
3.1 yrs

J. Grantham

TITLE
Chief Medical Officer of Cardiovascular
TENURE
2.8 yrs

Quill Turk

TITLE
Chief Medical Officer of Neuroendovascular
TENURE
0.8 yrs

Marty Leon

TITLE
External Consultant & Executive Advisor
TENURE
3.1 yrs
Board of Directors Tenure

Average tenure and age of the Corindus Vascular Robotics board of directors in years:

2.7
Average Tenure
58
Average Age
  • The average tenure for the Corindus Vascular Robotics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jeff Lightcap

TITLE
Chairman of the Board
AGE
59
TENURE
4.8 yrs

Mark Toland

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
48
TENURE
3.2 yrs

Jeff Gold

TITLE
Independent Director
COMPENSATION
$67K
AGE
70
TENURE
4.8 yrs

Campbell Rogers

TITLE
Independent Director
COMPENSATION
$59K
AGE
57
TENURE
3.3 yrs

Louis Cannon

TITLE
Director
COMPENSATION
$60K
AGE
60
TENURE
2.2 yrs

Nathan Harrington

TITLE
Director
COMPENSATION
$51K
AGE
50
TENURE
1.9 yrs

Jim Tobin

TITLE
Director
COMPENSATION
$48K
AGE
73
TENURE
1.2 yrs

Doug Braunstein

TITLE
Director
COMPENSATION
$49K
AGE
57
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Corindus Vascular Robotics insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Mar 19 Buy Louis Cannon Individual 27. Mar 19 27. Mar 19 10,000 $1.80 $18,000
13. Mar 19 Buy BioStar Ventures LLC Company 12. Mar 19 12. Mar 19 573,798 $1.38 $791,612
14. Mar 19 Buy Hudson Executive Capital LP Company 12. Mar 19 12. Mar 19 2,899,391 $1.38 $4,000,000
27. Aug 18 Buy Louis Cannon Individual 23. Aug 18 24. Aug 18 30,000 $1.03 $30,735
24. Aug 18 Buy Louis Cannon Individual 21. Aug 18 22. Aug 18 30,000 $0.99 $29,717
15. Aug 18 Buy Louis Cannon Individual 10. Aug 18 13. Aug 18 31,000 $0.96 $29,735
25. May 18 Buy Louis Cannon Individual 24. May 18 25. May 18 16,500 $0.80 $13,012
X
Management checks
We assess Corindus Vascular Robotics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corindus Vascular Robotics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CVRS News

Simply Wall St News

How Much Did Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) CEO Pocket Last Year?

In 2016 Mark Toland was appointed CEO of Corindus Vascular Robotics, Inc. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mark Toland's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does Market Volatility Impact Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) Share Price?

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

What You Must Know About Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) Financial Strength

(NYSEMKT:CVRS) is a small-cap stock with a market capitalization of US$161m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) Earnings Dropped -18%, Did Its Industry Show Weakness Too?

Investors may find my commentary, albeit very high-level and brief, on Corindus Vascular Robotics, Inc. … (NYSEMKT:CVRS) useful as an attempt to give more color around how Corindus Vascular Robotics is currently performing. … Furthermore, the company's loss seem to be growing over time, with the five-year earnings average of -US$28.9m

Simply Wall St -

What Kind Of Shareholder Appears On The Corindus Vascular Robotics Inc's (NYSEMKT:CVRS) Shareholder Register?

If you want to know who really controls Corindus Vascular Robotics Inc (NYSEMKT:CVRS), then you'll have to look at the makeup of its share registry. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Corindus Vascular Robotics is a smaller company with a market capitalization of US$233m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Corindus Vascular Robotics Inc (NYSEMKT:CVRS): Cash Is King

I will take you through Corindus Vascular Robotics’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … Free cash flow (FCF) is the amount of cash Corindus Vascular Robotics has left after it pays off its expenses, including its net capital expenditures, which is what the company needs to spend each year to maintain or grow its business operations. … The two ways to assess whether Corindus Vascular Robotics’s FCF is sufficient, is to compare the FCF yield to the market index yield, as well as determine whether the top-line operating cash flows will continue to grow

Simply Wall St -

How Much Did Corindus Vascular Robotics Inc's (NYSEMKT:CVRS) CEO Pocket Last Year?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mark Toland's Compensation Compare With Similar Sized Companies. … A first glance this seems like a real positive for shareholders, since Mark Toland is paid less than the average compensation paid by similar sized companies.

Simply Wall St -

Are Corindus Vascular Robotics Inc's (NYSEMKT:CVRS) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Corindus Vascular Robotics Inc (NYSEMKT:CVRS), with a market cap of US$173.83m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Corindus Vascular Robotics Inc (NYSEMKT:CVRS): Should The Recent Earnings Drop Worry You?

Today I will take a look at Corindus Vascular Robotics Inc's (NYSEMKT:CVRS) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past few years, as well as how the rest of the medical equipment industry performed. … View out our latest analysis for Corindus Vascular Robotics? … CVRS is loss-making, with the most recent trailing twelve-month earnings of -US$39.65m (from 31 March 2018), which compared to last year has become

Simply Wall St -

Corindus Vascular Robotics Inc's (NYSEMKT:CVRS) Profit Outlook

Corindus Vascular Robotics Inc's (NYSEMKT:CVRS):. … Corindus Vascular Robotics, Inc. … designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally.

Simply Wall St -

CVRS Company Info

Description

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

Details
Name: Corindus Vascular Robotics, Inc.
CVRS
Exchange: AMEX
Founded:
$595,986,342
206,223,648
Website: http://www.corindus.com
Address: Corindus Vascular Robotics, Inc.
309 Waverley Oaks Road,
Suite 105,
Waltham,
Massachusetts, 02452,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX CVRS New Common Stock NYSE MKT LLC US USD 13. Aug 2014
DB CR3 New Common Stock Deutsche Boerse AG DE EUR 13. Aug 2014
Number of employees
Current staff
Staff numbers
90
Corindus Vascular Robotics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:27
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/08
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.